Comparison of the effects of unfractionated heparin, low molecular weight heparin and hirudin (Revase™) on the fibrinolytic potential of cultured human umbilical vein endothelial cells

Fibrinolysis

Volumn 10, Issue 1, 1996, Pages 43-48

  Chorda C ^a   Paramo J A ^a   Rocha, E ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DALTEPARIN; DESULFATOHIRUDIN; HEPARIN; HIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE;

ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBRINOLYSIS; HUMAN; HUMAN CELL; NEWBORN; PRIORITY JOURNAL; UMBILICAL VEIN;

EID: 0029995376     PISSN: 02689499     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0268-9499(05)80075-X     Document Type: Article

References (37)

1. Levin E G. Latent tissue plasminogen activator produced by human endothelial cells in culture: evidence for an enzyme-inhibitor complex. Proc Natl Acad Sci USA 1983; 80: 6804-8.
2. Booyse F M, Osikowicz G, Feder S, Scheinbuks J. Isolation and characterization of a urokinase-type plasminogen activator (Mr=54 000) from cultured human endothelial cells indistinguishable from urinary urokinase. J Biol Chem 1984; 259: 7198-205.
3. Hekman C M, Loskutoff D J. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol chem 1985; 260: 11581-7.
4. Crutchley D J, Conanan L B. Endotoxin induction of an inhibitor of plasminogen activator in bovine pulmonary artery endothelial cells. J Biol Chem 1986; 261: 154-9.
5. Gelehrter T D, Snyzer-Laszuk R. Thrombin induction of plasminogen activator-inhibitor in cultured human endothelial cells. J Clin Invest 1984; 74: 1988-95.
6. Nawroth P P, Stern D M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5.
7. Schleef R R, Bevilacqua M P, Sawdey M, Gimbrone M A, Loskutoff D J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-5803.
8. Van Hinsberg V W M, Kooistra T, Koolwijk P. The vascular fibrinolytic system: pathophysiological modulation. Fibrinolysis 1993; 7(suppl. 1): 11-16.
9. Fisher A M, Merton R E, Marsh N A et al. A comparison of pentosan polysulphate and heparin. II. Effects of subcutaneous injection. Thromb Haemostas 1982; 47: 109-13.
10. Vairel E G, Brouty-Boye H, Toulemonde F, Doutremepuich C, Marsh N A, Gaffney P J. Heparin and a low molecular weight fraction enhances thrombolysis and by this pathway exercises a protective effect against thrombosis. Thromb Res 1983; 30: 219-24.
11. Bergqvist D, Nilsson I M. A sulphated polysaccharide. The effects in vivo and in vitro on the hemostatic system in healthy volunteers. Thromb Res 1981; 23: 309-15.
12. Greaves M, Preston F E, Kluft C, Bertina R M, Malia R G, Simms M. A comparative study of the influence of intramuscular stanozolol and subcutaneous heparin on coagulation and fibrinolysis following abdominal surgery. In: Davidson J F, Donati M B, Coccheri, eds. Progress in fibrinolysis, Vol. 7. Edinburgh: Churchill Livingstone, 1985: 105-7.
13. Jaffe E A, Nachman R L, Becker C G, Minick C R. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745-56.
14. Ohki M, Nakamura T, Morita T, Iwanaga S. A new endotoxin sensitivie factor associated with hemolymph coagulation system of horseshoe crab (Limulidae). FEBS Lett 1980; 120: 217-20.
15. Verheijen J H, Mullaart E M, Chang G T G, Kluft C, Wijngaards G. A simple, sensitive spectrophotometric assay for extrinsic (tissue-type) plasminogen activator applicable to measurements in plasma. Thromb Haemostas 1982; 48: 266-9.
16. Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427-36.
17. Bergsdorf N, Nilsson T, Wallen P. An enzyme linked immunosorbent assay for determination of tissue plasminogen activator applied to patients with thromboembolic disease. Thromb Haemost 1983; 50: 740-4.
18. Binnema D J, Van Iersel J J L, Dooijewaard G. Quantitation of urokinase antigen in plasma and culture media by use of an ELISA. Thromb Res 1986; 43: 569-77.
19. Declerck P J, Alessi M C, Verstreken M, Kruithof E K O, JuhanVague I, Collen D. Measurement of plasminogen activator inhibitor 1 in biological fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood 1988; 71: 220-5.
20. Webber K, Osborn M. The reliability of molecular weight determinations by dodecyl sulphate polyacrylamide gel electrophoresis. J Biol Chem 1969; 244: 4406-12.
21. Granelli-Piperno A, Reich E. A study of protease and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223-34.
22. Sakata Y, Loskutoff D J, Gladson C L, Hekman C M, Griffin J H. Mechanism of protein C-dependent clot lysis: role of plasminogen activator inhibitor. Blood 1986; 68: 1218-23.
23. Kaneko T, Wada H, Wakita Y et al. Enhanced tissue factor activity and plasminogen activator inhibitor 1 antigen in human umbilical vein endothelial cells incubated with lipoproteins. Blood Coag Fibrin 1994; 5: 385-92.
24. Van Deventer S J H, Büller H R, ten Cate J W, Aarden L A, Hack C E, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic and complement pathways. Blood 1990; 76: 2520-6.
25. Pirie-Shepherd S R, Blasco E, Pizzo S V. Heparin as an hyperbolic modulator of plasminogen activator by t-PA. Fibrinolysis 1994; 8: 182-8.
26. Marsh N A, Minter A J, Chesterman C N. The effect of heparin and other glycosaminoglycans on levels of tissue plasminogen activator and plasminogen activator inhibitor in cultured human umbilical vein endothelial cells. Blood Coag Fibrin 1990; 1: 133-8.
27. Ehrlich H J, Keijer J, Gebbink R K, Pannekoek H. Functional interaction of plasminogen activator inhibitor type 1 (PAI-l) and heparin. Biochemistry 1991; 30: 1021-8.
28. Vannucchi S, Pasquali F, Porciatti F, Chiarugi V, Magnelli L, Bianchini P. Binding, internalization and degradation of heparin and heparin fragments by cultured endothelial cells. Thromb Res 1988; 49: 373-83.
29. Bârzu T, Molho P, Tobelem G, Petitou M, Caen J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochem Biophys Acta 1985; 845: 196-203.
30. Dawes J. Interactions of heparins in the vascular environment. Haemostasis 1993; 23 (suppl. 1): 212-9.
31. Chanquía C J, Fontcuberta J, Fabra A, Rutilant M. Pro-fibrinolytic activity associated heparins on human umbilical vein endothelial cell cultures (HUVEC) in vitro. Fibrinolysis 1988; 2 (suppl. 1): 59 (abstract).
32. Konkle B A, Ginsburg D. The addition of endothelial cell growth factor and heparin to human umbilical vein endothelial cell cultures decreases plasminogen activator inhibitor-1 expression. J Clin Invest 1988; 82: 579-85.
33. Agnelli G, Borm J, Cosmi B, Levi M, ten Cate J W. Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis. Thromb Haemost 1988; 60: 311-13.
34. Grimaudo V, Omri A, Kruithof E K O, Hauert J, Bachmann F. Fibrinolytic and anticoagulant activity after a single subcutaneous administration of a low dose of heparin or a low molecular weight heparin-dihydroergotamine combination. Thromb Haemost 1988; 59: 388-91.
35. Aranda A, Páramo J A, Alfaro M J, Rocha E. The influence of standard and low molecular weight heparin on fibrinolysis in patients undergoing major abdominal surgery. Biol Clín Hematol 1987; 9: 169-74.
36. Aillaud M F, Elias A, Alessi M C et al. Treatment of deep vein thrombosis with low molecular weight heparin CY-222. Thrombolysis and plasma fibrinolytic parameters. Fibrinolysis 1986; (suppl. 1): 179 (abstract).
37. Electricwala A, Atkinson T. Effect on hirudin on tissue plasminogen activator induced clot lysis. Blood Coag Fibrin 1990; 1: 267-71.